产品
编 号：F751665
产品类型
规格
价格
是否有货
结构图
CAS No: 2375661-82-6
产品详情
生物活性：
Efdamrofusp alfa is a bispecific fusion protein. Efdamrofusp alfa is capable of neutralizing both VEGF isoforms and C3b/C4b. Efdamrofusp alfa can be used for the research of neovascular age-related macular degeneration (nAMD) and other complement-related ocular conditions.
体内研究：
Efdamrofusp alfa (13.5 μg; 3 days) inhibits activation ofthe complement system in a mouse model oflaser-induced CNV.Efdamrofusp alfa (1.35 mg; single intravitreal injection) shows favorable safety profiles and exhibited antiangiogenetic efficacy in a nonhuman primate laser-induced CNV model.Animal Model:C57BL/6J mice
Dosage:13.5 μg; 13.0 μg
Administration:3 days; 7days
Result:Significantly reduced C3d deposition.Reduced vascular leakage at 7 days after laser-induced injury.Significantly suppressed CNV formation 7 days after laser-induced injury. Reduced the concentrations of vitreous VEGF-A.
Animal Model:Rhesus monkeys
Dosage:1.35 mg
Administration:Single intravitreal injection
Result:Decreased the CNV leakage at 14 and 28 days and effectively reduced CNV volume 28 days.
体外研究：
Efdamrofusp alfa (0.135 mg/mL; 0, 6, 12, or 24 h) suppresses endothelial cell migration and tube formation. Efdamrofusp alfa (0-1000 μg/mL) inhibits complement activation in vitro.
Efdamrofusp alfa is a bispecific fusion protein. Efdamrofusp alfa is capable of neutralizing both VEGF isoforms and C3b/C4b. Efdamrofusp alfa can be used for the research of neovascular age-related macular degeneration (nAMD) and other complement-related ocular conditions.
体内研究：
Efdamrofusp alfa (13.5 μg; 3 days) inhibits activation ofthe complement system in a mouse model oflaser-induced CNV.Efdamrofusp alfa (1.35 mg; single intravitreal injection) shows favorable safety profiles and exhibited antiangiogenetic efficacy in a nonhuman primate laser-induced CNV model.Animal Model:C57BL/6J mice
Dosage:13.5 μg; 13.0 μg
Administration:3 days; 7days
Result:Significantly reduced C3d deposition.Reduced vascular leakage at 7 days after laser-induced injury.Significantly suppressed CNV formation 7 days after laser-induced injury. Reduced the concentrations of vitreous VEGF-A.
Animal Model:Rhesus monkeys
Dosage:1.35 mg
Administration:Single intravitreal injection
Result:Decreased the CNV leakage at 14 and 28 days and effectively reduced CNV volume 28 days.
体外研究：
Efdamrofusp alfa (0.135 mg/mL; 0, 6, 12, or 24 h) suppresses endothelial cell migration and tube formation. Efdamrofusp alfa (0-1000 μg/mL) inhibits complement activation in vitro.
产品资料
Copyright©2015-2024 沪ICP备2022026524号-1
沪公网安备